<DOC>
	<DOC>NCT00521586</DOC>
	<brief_summary>This study is to evaluate the safety, tolerability and immune response when 13-valent pneumococcal conjugate vaccine (13vPnC) and the trivalent inactivated flu vaccine (TIV) are given together to healthy adults aged 50-59 years who are naive to 23-valent pneumococcal polysaccharide vaccine (23vPS), or when the vaccines are given 1 month apart. It will also evaluate the immune response to 13vPnC once per year for 4 years and then to a second dose of 13vPnC given 5 years after the first dose.</brief_summary>
	<brief_title>Study Evaluating 13 Valent Pneumococcal Conjugate Vaccine With Trivalent Inactivated Influenza Vaccine</brief_title>
	<detailed_description />
	<mesh_term>Influenza, Human</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
	<criteria>Male or female aged 50 to 59 years Determined by medical history, physical examination and clinical judgement to be eligible for the study Able to complete electronic diary Available for the 5 year 9 month duration of the study Previous vaccination with any licensed or experimental pneumococcal vaccine Allergic to egg proteins and chicken proteins History of GuillianBarre syndrome Vaccination with TIV within 6 months before study start Vaccination with diphtheriacontaining vaccine within 6 months of study start Serious chronic disorders including immunodeficiency or metastatic malignancy Known or suspected hypersensitivity to any vaccine or vaccine component</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>59 Years</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>Pneumococcal Conjugate Vaccine</keyword>
</DOC>